SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

The new generic drug has been approved for treatment of bovine respiratory disease and associated pyrexia in beef and ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added to standard care in patients with moderate-to-severe lupus.

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Alteogen and Tesaro, a subsidiary of GSK, have entered an exclusive license agreement concerning a subcutaneous formulation of dostarlimab.

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points ...

TrumpRx is set to launch soon. President Donald Trump has been pressuring drug companies to lower prices. Americans currently pay about three times more for prescription medicine than patients in ...